Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation...
- Majority of Crohn’s disease is either mild or moderately severe
- Esanex starts dosing in Phase I combination trial for chronic lymphocytic leukaemia
- AstraZeneca’s Imfinzi looks to maintenance setting in advanced NSCLC to reverse fortunes
- Spyryx begins enrolment in Phase II cystic fibrosis trial of SPX-101
- BioLineRx launches Phase Ib/II combination trial of BL-8040 for gastric cancer
Majority of Crohn’s disease is either mild or moderately severe
Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gut.
Esanex starts dosing in Phase I combination trial for chronic lymphocytic leukaemia
Esanex has started dosing patients in a Phase I clinical trial of its drug candidate SNX-5422 combined with ibrutinib to target residual disease in patients with chronic lymphocytic leukaemia (CLL).
AstraZeneca’s Imfinzi looks to maintenance setting in advanced NSCLC to reverse fortunes
Since the disappointment of the Phase III MYSTIC trial failure earlier this year, AstraZeneca has redirected its efforts in non-small cell lung cancer to gaining approval in the second-line and maintenance settings.
Spyryx begins enrolment in Phase II cystic fibrosis trial of SPX-101
US-based biopharmaceutical firm Spyryx Biosciences has started patient enrolment in a Phase II clinical trial (HOPE-1) of its investigational candidate SPX-101 to treat cystic fibrosis (CF).
BioLineRx launches Phase Ib/II combination trial of BL-8040 for gastric cancer
Israeli biopharmaceutical firm BioLineRx and Genentech have launched a Phase Ib/II clinical trial of BL-8040 and atezolizumab (Tecentriq) in patients suffering from gastric cancer.
Tenapanor likely to makes waves in IBS-C space
On 11 October, Ardelyx reported positive results from a second pivotal Phase III trial (T3MPO-2) assessing the efficacy and safety of its lead product, tenapanor, which is under development for treatment of irritable bowel syndrome with constipation.
Ziopharm starts dosing in Phase I combination trial for paediatric brain tumours
US-based biotechnology firm Ziopharm Oncology has started dosing paediatric patients in a Phase I clinical trial of Ad-RTS-hIL-12 in combination with veledimex to treat brain tumours.
Chi-Med and AstraZeneca report data of savolitinib in two Phase Ib/II trials for NSCLC
Hutchison China MediTech and AstraZeneca have reported positive preliminary safety and clinical activity results of savolitinib from two Phase Ib/II combination trials for epidermal growth factor receptor (EGFR) mutation-positive (EGFRm) non-small cell lung cancer (NSCLC) with MET-amplification.
Sanofi and Regeneron report positive Phase II data of dupilumab for oesophagitis
Sanofi and Regeneron have reported positive results from a Phase II clinical trial of dupilumab for the treatment of adults with active moderate to severe eosinophilic oesophagitis.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.